Alglucerase

Pharmaceutical drug

A16AB01 (WHO)

Pharmacokinetic dataElimination half-life3.6–10.4 minIdentifiers

IUPAC name

Human beta-glucocerebrosidase

CAS Number

143003-46-7^Y

DrugBank

DB00088^Y

ChemSpider

none

UNII

27T56C7KK0

KEGG

D09675^Y

ChEMBL

ChEMBL1201633^N

Chemical and physical dataFormulaC₂₅₃₂H₃₈₅₄N₆₇₂O₇₁₁S₁₆Molar mass55597.64 g·mol⁻¹ ^NY (what is this?) (verify)

Alglucerase was a biopharmaceutical drug for the treatment of Gaucher's disease. It was a modified form of human β-glucocerebrosidase enzyme, where the non-reducing ends of the oligosaccharide chains have been terminated with mannose residues.^[1]

Ceredase is the trade name of a citrate buffered solution of alglucerase that was manufactured by Genzyme Corporation from human placental tissue.^[1] It is given intravenously in the treatment of Type 1 Gaucher's disease. This was the first drug approved as an enzyme replacement therapy.^[1]

It was approved by the FDA in 1991.^[2] It has been withdrawn from the market^[3]^[4] due to the approval of similar drugs made with recombinant DNA technology instead of being harvested from tissue; drugs made recombinantly, since there is no concern about diseases being transmitted from the tissue used in harvesting, and are less expensive to manufacture^[1] (see imiglucerase).

References

^ ^a ^b ^c ^d Deegan PB, Cox TM (2012). "Imiglucerase in the treatment of Gaucher disease: a history and perspective". Drug Design, Development and Therapy. 6: 81–106. doi:10.2147/DDDT.S14395. PMC 3340106. PMID 22563238.
^ World Health Organization. Regulatory Matters WHO Drug Information 5:3 1991. p 123
^ Aetna. Last reviewed 8 August 2014 Clinical Policy Bulletin Number: 0442: Enzyme-replacement Therapy for Lysosomal Storage Disorders
^ FDA Prescription and Over-the-Counter Drug Product List. 32ND Edition Cumulative Supplement Number 3: March 2012. Additions/Deletions for Prescription Drug Product List